NightBalance strengthens competitive position in sleep apnea market with key US and EU patent for innovative Sleep Position Trainer

Date: 19/08/2015

19 August 2015, Delft, the Netherlands – Today the European Patent office has granted NightBalance an important patent for their “method and device for sleep posture correction”, following the earlier grant by the US Patent and Trademark Office on July 30th 2015. The intellectual property covered by the patent provides broad protection for NightBalance’s Sleep Position Trainer (SPT).

“These patents provide us with vital IP protection in the largest and most attractive markets for sleep apnea,” said Eline Vrijland-van Beest, founder and CEO of NightBalance. “Together with the unique properties of our device, the SPT, its ease of use and the large clinical data set we have generated, it lays a solid basis for European expansion and for our US strategy – conducting clinical studies and file for US FDA 510k clearance in the near future.”

In the burgeoning field of sleep apnea innovation strong protection in the US and EU is vital. The SPT is CE marked since January 1, 2012, and is the first innovative OSA device in the world to be reimbursed by a major healthcare payer in the Netherlands, covering 5 million lives. NightBalance currently sells the SPT in 10 European countries through a network of specialized distributors.

The SPT is a smart device that gently trains patients not to sleep on their back (supine) to prevent apnea. Alternative treatment modalities such as continuous positive airway pressure (CPAP) or the use of a mandibular advancement devices (MAD) are considered effective, but invasive, uncomfortable, and complex. Among innovators in the sleep apnea market, NightBalance stands out because of the wealth of clinical data the company has already generated, demonstrating the efficacy and ease of use of its sleep position trainer, and a substantial increase in patient compliance.

NightBalance intends to raise a series B financing to support the further international commercial roll-out of the SPT, obtain reimbursement in other markets, and conduct studies to obtain 510(k) clearance from the US FDA.